Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Admedus Ltd awarded major supply contract with Royal Adelaide Hospital

Admedus Ltd (ASX:AHZ) has been awarded a major supply contract for the new Royal Adelaide Hospital (new RAH) for the installation of the arcomed Chroma Infusion pump system.

The new RAH is an 800 bed hospital which will provide world class healthcare and facilities for South Australians.

Manufactured by arcomed ag the Swiss made Chroma Infusion pumps offer an innovative whole-of-hospital system with smart pump technology.

The LCD touch screen, drug error reduction system and colour coding of medications on the screen increase patient safety and enhance clinical workflow.

The supply tender includes ongoing technical and clinical support and dedicated consumable products for use with the infusion systems over the coming 5 years.

Wayne Paterson, chairman and interim managing director, commented:

"We are encouraged by the uptake of arcomed Chroma Infusion pump systems within Australia which confirms both the quality and value to the health care system of the product range."

Increasing sales

For the period ending March 2015, YTD sales are up 49% to $9.7 million.

Quarterly sales were $3.3 million, 73% increase from the corresponding period last year.

Other key metrics include:

- CardioCel sales of $1.4 million - up 83% from the corresponding period;
- Infusion sales of $1.9 million - up 12% from the corresponding period; and
- 10th straight quarter of sales growth.

Analysis

Admedus remains focused on providing hospital-wide infusion solutions across the Australian and New Zealand healthcare systems.

The company has one of the largest infusion product ranges on market in Australia and New Zealand.

This demonstrates the company's ability to provide complex infusion solutions across hospitals and healthcare services groups.

Upcoming catalysts include the potential for additional supply contracts, with the company focused on multiple products across multiple regions.

The company is also working on commercial partnerships and collaborations on its immunotherapy and ADAPT technologies.

Admedus is also forecasting the strongest 4th quarter sales and record sales this financial year.

The company had $13 million in cash at the end of March 2016.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.